Castellano, Daniel
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. [artículo] - The Lancet. Oncology, 2014 - 15(11):1263-8.
Formato Vancouver:
Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN et al. Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014 Oct;15(11):1263-8.
PMID: 25242048
Contiene 13 referencias
Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. [artículo] - The Lancet. Oncology, 2014 - 15(11):1263-8.
Formato Vancouver:
Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN et al. Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014 Oct;15(11):1263-8.
PMID: 25242048
Contiene 13 referencias
Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.
